You may be here because someone you love has begun to struggle, or because your own brain health has become personal to you. Perhaps both.
Either way, this probably is not a casual search.
When the stakes feel this important, a confident promise can feel like relief. Taking a few minutes to ask better questions is not a failure to act. It is part of caring for the person you hope to help, including yourself.
The brain-supplement aisle is full of promises about focus, clarity, memory, mental energy, and healthy aging. Labels use phrases such as “clinically studied,” “doctor formulated,” and “science-backed.” Those words can mean very different things.
These are the seven questions I ask.
1. Is the noticeable effect nutrition, stimulation, or both?
Caffeine or another stimulant can make a person feel more alert quickly. That may be useful, but an immediate sensation does not prove longer-term nutritional support for brain health.
Read the label. Find the caffeine amount and serving size. Decide whether you are choosing short-term stimulation, daily nutrition, or both. The point is not “good” versus “bad.” It is knowing what you are buying and what the feeling can actually tell you.
2. Was the finished formula studied?
A bottle can contain several ingredients that have appeared in scientific papers. That is not the same as studying the combination in the bottle. Source, form, processing, amount, and the way ingredients are combined can all differ.
Ask precisely: Was this finished formula studied at the amount being sold to me?
If an earlier or similar formula was studied, ask what changed. “Contains researched ingredients” and “this finished product was studied” are different claims.
3. Was the research conducted in people?
Laboratory and animal studies can help researchers understand a mechanism and decide whether a question deserves a human trial. They do not establish that a person taking the marketed product will experience the same result.
Ask for human evidence that matches the promise. Then ask whether the people studied resemble the person you hope to help.
4. Who took what, how much, and for how long?
A positive headline is not enough. Look for the participants’ age and health, the number who enrolled and completed the study, the exact intervention and dose, how long they took it, and what researchers measured.
A one-day attention test in healthy young adults cannot answer a long-term question about an older adult with a health condition. A result at a research dose cannot be quietly transferred to a smaller amount on today’s label.
Population, dose, duration, and outcome are not fine print. They are the boundaries of the evidence.
5. What does the design allow us to conclude?
Randomization, blinding, a comparison group, suitable measures, enough participants, and independent replication can increase confidence that an intervention produced an observed change.
An open-label study without a control group can reveal a signal worth pursuing. It cannot isolate cause and effect with the confidence of a well-designed randomized controlled trial. Confidence grows when findings hold up across additional studies.
“This deserves a better study” is not the same as “this product caused the result.”
6. Are the limitations as easy to find as the positive result?
Was the study small? Did everyone know what they were taking? Did every important measure improve? Has the formula or dose changed? Has another team repeated the finding?
Those facts do not erase a study. They tell you how much weight it can carry.
A limitation should sit beside the result it qualifies, especially when a company is discussing research connected to its own product.
7. Can I examine the bottle and the company as carefully as the paper?
Read the complete label. Look at ingredient forms, serving amounts, stimulants, fillers, allergens, and quality information. Compare cost per recommended day, not only the price on the front.
Then look beyond the bottle. Who stands behind it? Can you find that person’s relevant work, publications, and contact information? Does the company answer difficult questions, or only repeat benefits?
If you take medications or other supplements, have a medical condition, are pregnant or nursing, or are preparing for surgery, review the ingredients with a qualified health professional. “Natural” does not mean appropriate for every person.
I have authored more than 180 peer-reviewed publications and served as principal investigator on more than 30 clinical studies. When I encounter a marketing claim, that experience has not made my first question more complicated. It has made it simpler:
Show me the research. Give me the PubMed record or a link to the journal article so I can read the paper.
That is not hostility toward supplements. I have spent much of my career studying nutrition and dietary supplementation in people. It is respect for the person making the decision. Evidence should be available for inspection, not used as decoration.
Now Let Me Ask Those Same Questions About Daily Brain Care
A scientific standard means very little if I will not apply it to work bearing my own name.
What We Actually Studied
Dr. H. Reginald McDaniel and I came to this study after years of investigation into aloe, rice bran, and complex plant carbohydrates. The ingredients were chosen for scientific reasons. We expected the formula to help and wanted to find out what a human study would show.
Expectation is not evidence. It is the reason to do the study.
In 2013, my colleagues and I published the results of a 12-month human pilot study in the Journal of Alzheimer’s Disease. We studied an aloe polymannose multinutrient complex, or APMC, in adults with moderate-to-severe Alzheimer’s disease. To ensure the diagnosis was established, it had to have been made at least one year before enrollment and was verified by the study psychiatrist.
Thirty-four people enrolled, and 26 completed the 12-month intervention. Their average age was 79.9, with ages ranging from 60 to 98. Many were also living with diabetes, depression, heart disease, or other serious conditions affecting far more than cognitive function. They remained on medications ordered by their treating physicians, and they also did not change their diet, exercise, socialization, or any other behavior during the study, with the exception of necessary intervention for a medical emergency.
This was a population often left out of research because of disease severity or other medical conditions. We wanted to include people whose need was substantial, not only those easiest to study.
Their caregivers made that possible. They administered approximately 2.5 grams of the formula four times a day, for roughly 10 grams daily, and brought their family members through repeated testing over a full year. They were among the most committed study partners I have ever encountered. Their consistency came from the same place that brings many people to this article: they wanted to help someone they loved.
Cognitive testing took place at the beginning and at months 3, 6, 9, and 12. Blood was collected at the beginning and month 12 to examine inflammatory and immune measures. The study was reviewed and approved by an institutional review board, and informed consent was obtained from each participant and/or primary caregiver.
It was also open-label and single-arm. Everyone received the formula, everyone knew it, and there was no placebo or other control group.
Why We Chose Not to Use a Placebo Group
That choice was deliberate.
We had limited funding to conduct the study. We also had families living with an unforgiving condition and looking for any responsible opportunity to help someone they loved.
Years of prior work gave us a reason to expect the formula might help. The families wanted access to that possibility. Caregivers told me they would not have enrolled their loved one if there were a 50 percent chance of receiving a placebo instead. Their hope was understandable; benefit was still unproven.
For this particular first-stage study, Reg and I did not believe that was the right request to make of them. That was our project-specific judgment, not a declaration that every placebo-controlled Alzheimer’s study is unethical.
We understood the tradeoff.
Giving every participant the intervention helped us include a difficult, medically complicated group and answered the families’ practical concern. It also meant we could not separate the intervention from expectation, test familiarity, natural fluctuation, ongoing care, or other explanations with the confidence a control group can provide. We asked caregivers to keep daily routines the same unless medical needs required a change. That instruction did not rule out other influences on the results.
We knowingly accepted less scientific certainty. We hoped that if the pilot produced a meaningful signal, it would open the door to the larger, controlled study needed next.
That is what we studied, why we made the design choice, and what the choice cost scientifically.
Now here is what happened.
The Result That Changed the Direction of My Work
On the ADAS-Cog, widely regarded as a gold standard for assessing cognition in Alzheimer’s research, the group’s average score improved from its starting point at months 9 and 12. At months 9 and 12, the average improvement was 4.2 points. The improvement was statistically significant, and its size exceeded the four-point threshold the assessment uses to identify clinically meaningful change.
These were people nearly 80 years old on average, living with established moderate-to-severe disease, and often alongside other serious health conditions. On this measure, we saw significant improvement from where they had started. That was a finding that not only was a first in my career, but was and still is unlike any other in the scientific literature.
The cognitive finding was not alone. Blood analyses also found lower levels of two proteins associated with inflammation and changes in the function and balance of certain immune cells. The proportion of CD14+ cells, a cell population with progenitor properties, rose to nearly four times its starting level. These findings were also unlike any other that had been shown to this point in the scientific literature and still have not been duplicated by scientists studying other interventions, such as exercise, diet, and hyperbaric oxygen. Although not conclusively definitive due to the nature of the study, our results were first-time findings in this patient population showing insight into the relationships between immune function and cognition.
Not every measure improved. Another brief cognitive test showed no statistically significant change, while a different cognitive test and everyday-function scores worsened. Many of the other immune markers also did not change, but that did not dampen our enthusiasm for what the study showed, again based on the uniqueness of the findings in comparison to every other type of intervention that has been utilized to try to help people with Alzheimer’s.
Even with the study’s limitations, our work was new to the field of Alzheimer's, particularly in the people we studied at the worst severity level. Because of the years of work that Reg and his previous colleagues had put into the study of these polysaccharides and how many effects they had documented and witnessed, our study’s findings were another step in that process and one that fueled me into thinking about where the study could lead me in my career.
It was a day I will never forget. When the statistics rolled in, I felt like screaming to the rooftops and throwing a party. I immediately called Reg to share the news.
Reg is one of the smartest people I have ever known, and one of the most stoic. Even he was thrilled by what we had found.
It was the single most defining watershed moment of my academic career and my entire professional life.
That excitement gave me a reason to want to keep the research going.
Why I Took the Research Beyond the University
After the first of four papers from the study was published in 2013, I sought support from the National Institutes of Health and the Alzheimer’s Association to extend the work. I believed the findings from the first study would help us secure funding for the next study.
That support did not materialize.
However, because of what we had shown in this study, I was compelled to continue learning more and doing everything I could to extend it. Reg had spent years working in this field, and I wanted him to know I had taken the baton and done something meaningful with it. I wanted the nutrition behind the research to reach people beyond those we could enroll in a trial.
Leaving full-time academia to build a nutrition business had not been my original plan. In 2017, I made that change, retaining a voluntary appointment at the University of Miami. My daily work shifted toward making this nutritional approach accessible, with the longer-term goal of funding more research myself. Daily Brain Care grew out of that commitment.
The following January, in 2018, Pfizer announced it was ending investment in its internal neuroscience discovery and early-development programs, including Alzheimer’s research. Even an organization with those resources was stepping back from that work. Other researchers continued; the field had not stopped.
My own change of direction had already happened. Pfizer’s decision puts the difficulty of the field in perspective.
Some controlled trials in progressive disease measure slower decline against a comparison group. Our pilot recorded improvement from the participants’ own baseline on one cognitive measure. Those are different comparisons; they cannot establish which approach is better.
That difficulty is one reason I ask you to look closely when any company promises a life-changing result. An encouraging observation deserves investigation. A promise to you requires evidence that actually supports it.
The study was an eye-opener for me based on the significance of the findings, and it changed the course of what I wanted to do with the rest of my professional life.
What Changed Between the Study Formula and Daily Brain Care Today
The current Daily Brain Care formula grew from that work, and it is almost identical to the intervention used in the 2013 study.
Among the changes, a tiny amount of fish-oil spherules was removed to accommodate vegetarians. The flaxseed content was increased slightly to account for the removed omega-3 source. Flaxseed is a rich source of ALA, a plant-based omega-3.
Soy lecithin was replaced with sunflower lecithin to accommodate people with soy concerns while retaining lecithin’s intended role in the formula.
The amount taken also changed. The study used approximately 10 grams daily in four servings. Today’s suggested powder use is one scoop twice daily, a lower daily amount.
Those distinctions matter. The earlier study does not prove that today’s formula at today’s suggested serving will produce the same outcomes. It does not establish that Daily Brain Care treats or prevents Alzheimer’s disease, and it cannot predict what any individual will experience.
I can be deeply encouraged by the research and tell you plainly where its evidence ends. Both belong in this story.
Where This Leaves You, and the Person You Care About
If you came here looking for someone you love, that person is still at the heart of this conversation. You deserve useful answers about what you are considering for them.
Along the way, you may also have begun to wonder about your own daily brain health routine. If your own concerns brought you here in the first place, this conversation has been for you all along.
Daily Brain Care brings my work into a whole-food formula built around concentrated plant polysaccharides from aloe vera and stabilized rice bran. It contains no caffeine or stimulants and was created for daily nutritional support of brain health and healthy aging.* I take it myself every day.
The pilot does not establish prevention of cognitive decline in healthy adults. My invitation is to consider daily nutrition alongside nourishing food, sleep, movement, mental engagement, and appropriate medical care, not in place of them. Daily Brain Care is one way to bring these concentrated plant ingredients into that routine. Our product is also a source of polysaccharides that are largely missing from the modern diet and yet have been shown to be so beneficial, not only through our research, but by scientists from around the world.
Whether you are here for yourself, someone you love, or both, I want you to find support you feel good about pursuing. Your well-being matters to me, regardless of what you may be exploring.
If what I have shared resonates with you, I invite you to take a closer look at what I have created with Daily Brain Care.
TAKE A CLOSER LOOK AT DAILY BRAIN CARE.
